key: cord-0056872-clu5esdk
authors: Maurizi, Niccolò; Fumagalli, Carlo; Cecchi, Franco; Olivotto, Iacopo
title: Use of Smartphone-operated ECG for home ECG surveillance in COVID-19 patients
date: 2021-01-29
journal: nan
DOI: 10.1093/ehjdh/ztab009
sha: ef8b113336746f3db05bc8aca29eb21a8d569630
doc_id: 56872
cord_uid: clu5esdk

nan

Current COVID-19 pandemic is challenging hospital capacity and health care workers. In such setting, it's imperative to properly select stable COVID-19 patients to be treated at home. Therefore, empowering family physicians and their patients with accurate and portable home diagnostic devices, including electrocardiogram (ECG) devices and oximeters, to early identifies those with evolutive potential becomes a priority (1) . However, limited data exist on the role of ECG as home monitoring tool for COVID-19 stable patient (2) . We evaluated the use of a portable 8/12

leads Smartphone-operated ECG device for self-home ECG recording, the prevalence of ECG abnormalities and predictors of short-term hospitalization in COVID-19 patients treated at home.

From March to October 2020, we provided 21 family physicians with a previously validated portable hospital-grade 8/12-Lead Smartphone-operated ECG device (D-Heart, sampling frequency 640 Hertz) (2) approved for homecare to enable ECG recording of COVID-19 infected nonhospitalized patients (positive nasal-swab PCR). First ECG was operated by the patient at home with the supervision of the family physician, than the device was left to the patients to record at least 1 ECG at day 4 of infection or whenever a cardiac symptom was present for the first 10 days of infection. Included patients had the ability to properly use smartphone's basic functions. Patients were instructed to record a 12-lead ECG in case of ischemia related symptoms; in all other cases, an 8-Lead ECG was performed (including DI, DII, DIII, aVR, aVL, aVF, V2 and V5). ECG recording length was 12 seconds, interpretation was performed by 3 cardiologists via a telecardiology platform 24/7 within 15 minutes from ECG arrival. ECG alterations were classified following current standards (3) . QT interval was measured manually in lead II and V5 for each ECG: mean value was used for QTc calculation, corrected with Bazzett formula (4 Fig. 2) . Of note, 3 had prior myocardial infarction.

As the coronavirus pandemic is radically transforming our health care systems, it's crucial to preserve hospital capacity by empowering family physician and their patients with appropriate tools to early identifies those with a worse short-term clinical deterioration.

We report here that home ECG monitoring of non-hospitalized COVID-19 patients can identifies disease-related cardiac complications and that the presence of ECG alterations at COVID-19 diagnosis independently predicts, together with age and comorbidities, the risk of short-term hospitalisation in the first 10 days of the disease. Moreover, outpatient QTc monitoring was feasible, identifying in 3% of patients who underwent during the first pandemic the no longer encouraged Hydroxychloroquine/Azithromycin therapy a significant QTc prolongation.

ECG may help stratify patients not only by revealing acute changes, such as ST-segment/T wave abnormalities or possible new arrhythmias/conduction disorders, but also by showing chronic abnormalities suggesting an underlying cardiac disease, already been associated with worse COVID-19 prognosis (1), but also identifies those with a worse short-term clinical outcome.

No previous study, however, assessed the performance of smartphone ECG devices in the setting of home monitoring of patients with stable COVID-19. Smartwatches and other smartphone ECG devices, despite being extremely portable, easy to use and ideal for simple arrhythmias assessment (5,6), might not be adequate to complete evaluation of patients with complex ECG alterations, as ST/T changes, where all precordial leads should be available (3).

Evidences are emerging suggesting a potential role of multi-parametric tele-monitoring for stable COVD-19, but whether this should be regularly performed or be limited to specific subgroups of patients should still be clarified. Further studies are needed addressing its impact on outcome on a population scale. 

Electrocardiographic findings at presentation and clinical outcome in patients with SARS-CoV-2 infection

Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®)

AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology

AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the

Smartwatch performance for the detection and quantification of atrial fibrillation

Home Monitoring of Cardiac Devices in the Era of COVID-19